joae tirzepatide glp-1 Stopping Receptor Agonists… Why and How to Plan an “Exit Strategy” for Your Patients Tirzepatide | DirectMeds

GLP-1 Users Are Creating a New Consumer Profile The rise of GLP-1 medications is creating one of the most significant shifts in consumer behavior we have seen in years

Outbred ICR (CD-1 IGS) mice were used for this experiment

Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies

Other concerning features that warrant prompt medical attention include: new headache onset after age 50, headache during pregnancy or postpartum period, headache with fever or neck stiffness, headache following head trauma, headache in immunocompromised patients, and headache that worsens with position changes or Valsalva maneuver (coughing, straining)

Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)

Macroautophagy is defective in mucolipin-1-deficient mouse neurons